Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit

Group 1 - Eliem Therapeutics, Inc. will participate in the Stifel 2024 Virtual Immunology and Inflammation Summit on September 17-18, 2024 [1] - The summit will feature 1x1 meetings format for discussions [1] - Eliem Therapeutics focuses on developing therapeutics for autoimmune-driven inflammatory diseases, including budoprutug, an anti-CD19 antibody [1] Group 2 - Budoprutug is designed for a broad range of autoimmune diseases, such as systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy [1]